Maturitas
Volume 61, Issue 4 , Pages 305-309 , 20 December 2008

Hormone replacement therapy use and the risk of stroke

  • Christel Renoux

      Affiliations

    • McGill Pharmacoepidemiology Research Unit, Jewish General Hospital, Departments of Epidemiology and Biostatistics and of Medicine, McGill University, Montreal, Canada
    • ,
  • Sophie Dell’Aniello

      Affiliations

    • McGill Pharmacoepidemiology Research Unit, Jewish General Hospital, Departments of Epidemiology and Biostatistics and of Medicine, McGill University, Montreal, Canada
    • ,
  • Edeltraut Garbe

      Affiliations

    • Department of Clinical Epidemiology, Bremen Institute for Prevention Research and Social Medicine, University of Bremen, Germany
    • ,
  • Samy Suissa

      Affiliations

    • McGill Pharmacoepidemiology Research Unit, Jewish General Hospital, Departments of Epidemiology and Biostatistics and of Medicine, McGill University, Montreal, Canada
    • Corresponding Author InformationCorresponding author at: Center for Clinical Epidemiology, Jewish General Hospital, 3755 côte Sainte-Catherine, Montreal, Québec, Canada H3T 1E2. Tel.: +1 514 340 8222; fax: + 1 514 340 7564.

Received 19 February 2008 ,Revised 4 September 2008 ,Accepted 20 September 2008.

References 

  1. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Int Med. 1992;117(December (12)):1016–1037
  2. Barrett-Connor E, Grady D. Hormone replacement therapy, heart disease, and other considerations. Annu Rev Public Health. 1998;19:55–72
  3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.. JAMA. 2002;288(July (3)):321–333
  4. Reed MJ, Kloosterboer HJ. Tibolone: a selective tissue estrogenic activity regulator (STEAR). Maturitas. 2004;48(August (Suppl. 1)):S4–S6
  5. Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008;359(August (7)):697–708
  6. Garcia Rodriguez LA, Perez GS. Use of the UK General Practice Research Database for pharmacoepidemiology. Br J Clin Pharmacol. 1998 May;45(5):419–425
  7. Jick SS, Kaye JA, Vasilakis-Scaramozza C, et al. Validity of the general practice research database. Pharmacotherapy. 2003;23(May (5)):686–689
  8. Jick H, Jick SS, Derby LE. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. BMJ. 1991;302(March (6779)):766–768
  9. Andersohn F, Schade R, Suissa S, Garbe E. Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case–control study. Stroke. 2006;37(July (7)):1725–1730
  10. Archer DF, Hendrix S, Gallagher JC, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab. 2007;92(March (3)):911–918
  11. Beral V, Green J, Reeves G, Bull D. Fatal stroke in postmenopausal users of tibolone and hormonal therapy. BMJ. 2006;24(October):Ref Type: Generic
  12. Shapiro S. Adverse neoplastic and cardiovascular outcomes of HRT: the validity of the evidence. Endocrine. 2004;24(August (3)):203–210
  13. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med. 2001;345(October (17)):1243–1249
  14. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 2003;289(May (20)):2673–2684
  15. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation. 2006;113(May (20)):2425–2434
  16. Vogelvang TE, van der Mooren MJ, Mijatovic V. Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications. Treat Endocrinol. 2004;3(2):105–115
  17. Kloosterboer HJ, Ederveen AG. Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (+/−progestogen) treatments. J Steroid Biochem Mol Biol. 2002;83(December (1–5)):157–165
  18. Nelson HD. Menopause. Lancet. 2008;371(March (9614)):760–770
  19. Kloosterboer HJ. Tissue-selectivity: the mechanism of action of tibolone. Maturitas. 2004;48(August (Suppl. 1)):S30–S40
  20. Winkler UH, Altkemper R, Kwee B, Helmond FA, Coelingh Bennink HJ. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertil Steril. 2000;74(July (1)):10–19
  21. Bjarnason NH, Bjarnason K, Haarbo J, Bennink HJ, Christiansen C. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab. 1997;82(June (6)):1752–1756
  22. Simoncini T, Mannella P, Fornari L, et al. Tibolone activates nitric oxide synthesis in human endothelial cells. J Clin Endocrinol Metab. 2004;89(September (9)):4594–4600
  23. Cicinelli E, Ignarro LJ, Galantino P, Pinto V, Barba B, Schonauer S. Effects of tibolone on plasma levels of nitric oxide in postmenopausal women. Fertil Steril. 2002;78(September (3)):464–468
  24. Haenggi W, Linder HR, Birkhaeuser MH, Schneider H. Microscopic findings of the nail-fold capillaries—dependence on menopausal status and hormone replacement therapy. Maturitas. 1995;22(June (1)):37–46
  25. Dansuk R, Unal O, Karageyim Y, Esim E, Turan C. Evaluation of the effect of tibolone and transdermal estradiol on triglyceride level in hypertriglyceridemic and normotriglyceridemic postmenopausal women. Gynecol Endocrinol. 2004;18(May (5)):233–239
  26. Milner MH, Sinnott MM, Cooke TM, Kelly A, McGill T, Harrison RF. A 2-year study of lipid and lipoprotein changes in postmenopausal women with tibolone and estrogen-progestin. Obstet Gynecol. 1996;87(April (4)):593–599
  27. Clarkson TB, Anthony MS, Mikkola TS, St Clair RW. Comparison of tibolone and conjugated equine estrogens effects on carotid artery atherosclerosis of postmenopausal monkeys. Stroke. 2002;33(November (11)):2700–2703
  28. Zandberg P, Peters JL, Demacker PN, Smit MJ, de Reeder EG, Meuleman DG. Tibolone prevents atherosclerotic lesion formation in cholesterol-fed, ovariectomized rabbits. Arterioscler Thromb Vasc Biol. 1998;18(December (12)):1844–1854
  29. Bots ML, Evans GW, Riley W, et al. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tibolone (OPAL) study. Eur Heart J. 2006;27(March (6)):746–755
  30. Castelo-Branco C, Garcia-Fantini M, Haya J. Vascular reactivity and atheromatous plaques in post-menopausal women on tibolone treatment. Open prospective study with Doppler ultrasonography in internal carotid artery. Maturitas. 2005;50(April (4)):259–265
  31. Erenus M, Ilhan AH, Elter K. Effect of tibolone treatment on intima-media thickness and the resistive indices of the carotid arteries. Fertil Steril. 2003;79(February (2)):268–273
  32. Hall GC, Brown MM, Mo J, MacRae KD. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology. 2004;62(February (4)):563–568

PII: S0378-5122(08)00254-5

doi: 10.1016/j.maturitas.2008.09.020

Maturitas
Volume 61, Issue 4 , Pages 305-309 , 20 December 2008

Article Tools

* Image Usage & Resolution